Velan Capital Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Velan Capital Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-55,300	Closed	-$3.15M	–	28
2023 Q3	$3.15M	Hold	55,300	–	–	2.54%	10
2023 Q2	$2.82M	Buy	55,300 +31,900	+136%	+$858K	2.62%	15
2023 Q1	$501K	Buy	+23,400	New	+$393K	0.43%	27

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Velan Capital Investment Management's MLTX Position: Q4 2023 in Review

Velan Capital Investment Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 55,300 shares — an estimated $3.15M sold.

Velan Capital Investment Management first reported a position in MLTX in Q1 2023 and held it in 3 quarters. The position peaked at $3.15M in Q3 2023. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

Velan Capital Investment Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
Velan Capital Investment Management sold 55,300 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $3.15M.
Velan Capital Investment Management first reported a position in MoonLake Immunotherapeutics in Q1 2023 and held it in 3 quarters.
Velan Capital Investment Management's MoonLake Immunotherapeutics position peaked at $3.15M in Q3 2023.
125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on Velan Capital Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.